deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02432378

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

A PHASE 2 EFFICACY TRIAL OF INTENSIVE LOCOREGIONAL CHEMOIMMUNOTHERAPY FOR ADVANCED STAGE OVARIAN CANCER AND TUMOR-SPECIFIC INTRANODAL AUTOLOGOUS ALPHA-DC1 VACCINES

Sponsor: AIM ImmunoTech Inc.

Conditions Cancer of Ovary Cancer of the Ovary Neoplasms, Ovarian Ovarian Cancer Ovary Cancer Ovary Neoplasms
Interventions Cisplatin + CKM + Celecoxib + DC Vaccine Cisplatin + celecoxib + DC vaccine
Updated 22 times since 2017 Last updated: Jun 18, 2025 Started: Sep 4, 2015 Primary completion: Jun 19, 2025 Completion: Jun 19, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

lack of funding

Other terminated trials from AIM ImmunoTech Inc.

More terminations from AIM ImmunoTech Inc.

Listed as NCT02432378, this PHASE1/PHASE2 trial focuses on Cancer of Ovary and Cancer of the Ovary and remains terminated or withdrawn. Sponsored by AIM ImmunoTech Inc., it has been updated 22 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Oct 2020 · 7 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Nov 2021 · 8 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Nov 2022 · 10 months · monthly snapshot~Nov 2022 – ~Jun 2024 · 19 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – present · 12 months · monthly snapshot

Change History

22 versions recorded

  1. Jul 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

    Status: Suspended → Terminated

  2. Jun 2025 — Jul 2025 [monthly]

    Suspended PHASE1/PHASE2

    Status: Recruiting → Suspended

  3. Oct 2024 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Status: Suspended → Recruiting

  5. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 17 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Suspended PHASE1_PHASE2

  2. Nov 2022 — Jun 2024 [monthly]

    Suspended PHASE1_PHASE2

  3. Jan 2022 — Nov 2022 [monthly]

    Suspended PHASE1_PHASE2

  4. Nov 2021 — Jan 2022 [monthly]

    Suspended PHASE1_PHASE2

  5. Mar 2021 — Nov 2021 [monthly]

    Suspended PHASE1_PHASE2

  6. Jan 2021 — Mar 2021 [monthly]

    Suspended PHASE1_PHASE2

  7. Oct 2020 — Jan 2021 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  8. Mar 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Active Not Recruiting → Recruiting

  9. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Jul 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Apr 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Dec 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  13. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  15. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  16. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AIM ImmunoTech Inc.
  • National Cancer Institute (NCI)
  • Roswell Park Cancer Institute
  • University of Pittsburgh
Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations